Read by QxMD icon Read

Rheumatoid arthritis

shared collection
20 papers 500 to 1000 followers
I Hafström, B Ringertz, A Spångberg, L von Zweigbergk, S Brannemark, I Nylander, J Rönnelid, L Laasonen, L Klareskog
OBJECTIVE: Whether food intake can modify the course of rheumatoid arthritis (RA) is an issue of continued scientific and public interest. However, data from controlled clinical trials are sparse. We thus decided to study the clinical effects of a vegan diet free of gluten in RA and to quantify the levels of antibodies to key food antigens not present in the vegan diet. METHODS: Sixty-six patients with active RA were randomized to either a vegan diet free of gluten (38 patients) or a well-balanced non-vegan diet (28 patients) for 1 yr...
October 2001: Rheumatology
Ivy Y Choi, Danielle M Gerlag, Marieke J Herenius, Rogier M Thurlings, Carla A Wijbrandts, Dirk Foell, Thomas Vogl, Johannes Roth, Paul P Tak, Dirk Holzinger
BACKGROUND: One-third of rheumatoid arthritis (RA) patients treated with biological therapy show lack of response. The use of predictive biomarkers to identify responders to treatment may provide guidance in optimising treatment strategies and reduce unnecessary side effects and costs. OBJECTIVE: To test the ability of myeloid-related proteins (MRP)8/14 protein complexes, an endogenous TLR-4 receptor agonist, to predict and monitor response to biologics in RA patients...
March 2015: Annals of the Rheumatic Diseases
Nicolino Ruperto, Hermine I Brunner, Pierre Quartier, Tamás Constantin, Nico Wulffraat, Gerd Horneff, Riva Brik, Liza McCann, Ozgur Kasapcopur, Lidia Rutkowska-Sak, Rayfel Schneider, Yackov Berkun, Inmaculada Calvo, Muferet Erguven, Laurence Goffin, Michael Hofer, Tilmann Kallinich, Sheila K Oliveira, Yosef Uziel, Stefania Viola, Kiran Nistala, Carine Wouters, Rolando Cimaz, Manuel A Ferrandiz, Berit Flato, Maria Luz Gamir, Isabelle Kone-Paut, Alexei Grom, Bo Magnusson, Seza Ozen, Flavio Sztajnbok, Karine Lheritier, Ken Abrams, Dennis Kim, Alberto Martini, Daniel J Lovell
BACKGROUND: Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1β monoclonal antibody, in two trials. METHODS: In trial 1, we randomly assigned patients, 2 to 19 years of age, with systemic JIA and active systemic features (fever; ≥2 active joints; C-reactive protein, >30 mg per liter; and glucocorticoid dose, ≤1.0 mg per kilogram of body weight per day), in a double-blind fashion, to a single subcutaneous dose of canakinumab (4 mg per kilogram) or placebo...
December 20, 2012: New England Journal of Medicine
Susan M Goodman, Bruce N Cronstein, Vivian P Bykerk
OBJECTIVES: Methotrexate (MTX) is considered the 'anchor drug' in the therapy of rheumatoid arthritis (RA), yet many physicians do not optimise MTX regimens in spite of high RA disease activity. The recent development of an auto-injector for the subcutaneous (subQ) administration of MTX has prompted re-evaluation of MTX utilisation. The purpose of this systematic literature review is to determine the optimal dose, drug level, and route of administration for MTX in the context of relevant pharmacokinetics and pharmacogenomics...
March 2015: Clinical and Experimental Rheumatology
Ronald F van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A García Meijide, Sylke Wagner, Sarka Forejtova, Samuel H Zwillich, David Gruben, Tamas Koncz, Gene V Wallenstein, Sriram Krishnaswami, John D Bradley, Bethanie Wilkinson
BACKGROUND: Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for the treatment of rheumatoid arthritis. METHODS: In this 12-month, phase 3 trial, 717 patients who were receiving stable doses of methotrexate were randomly assigned to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, 40 mg of adalimumab once every 2 weeks, or placebo. At month 3, patients in the placebo group who did not have a 20% reduction from baseline in the number of swollen and tender joints were switched in a blinded fashion to either 5 mg or 10 mg of tofacitinib twice daily; at month 6, all patients still receiving placebo were switched to tofacitinib in a blinded fashion...
August 9, 2012: New England Journal of Medicine
Yune-Jung Park, Ji-Young Kim, Jeongmi Park, Jin-Jung Choi, Wan-Uk Kim, Chul-Soo Cho
Objective: To identify factors influencing endothelial progenitor cell (EPC) counts in patients with rheumatoid arthritis (RA). Methods: The number of circulating CD34+/VEGFR2+ EPCs was measured in 126 RA patients and 46 non-RA controls. Endothelial function was assessed by brachial flow-mediated dilation (FMD). Serum CXCL12 concentration was determined using an enzyme-linked immunosorbent assay. EPCs and FMD were measured at baseline and after 24 weeks of anti-tumor necrosis factor-α (TNF-α) therapy in 29 patients with active RA...
January 8, 2014: Arthritis and Rheumatism
Stephanie Lefèvre, Anette Knedla, Christoph Tennie, Andreas Kampmann, Christina Wunrau, Robert Dinser, Adelheid Korb, Eva-Maria Schnäker, Ingo H Tarner, Paul D Robbins, Christopher H Evans, Henning Stürz, Jürgen Steinmeyer, Steffen Gay, Jürgen Schölmerich, Thomas Pap, Ulf Müller-Ladner, Elena Neumann
Active rheumatoid arthritis originates from few joints but subsequently affects the majority of joints. Thus far, the pathways of the progression of the disease are largely unknown. As rheumatoid arthritis synovial fibroblasts (RASFs) which can be found in RA synovium are key players in joint destruction and are able to migrate in vitro, we evaluated the potential of RASFs to spread the disease in vivo. To simulate the primary joint of origin, we implanted healthy human cartilage together with RASFs subcutaneously into severe combined immunodeficient (SCID) mice...
December 2009: Nature Medicine
Alan M Rathbun, Leslie R Harrold, George W Reed
OBJECTIVES: Depression is a common and important comorbidity in patients with rheumatoid arthritis (RA). The study aim was to describe rates of depressive symptoms and their associations with RA disease activity using measures reported from patients and rheumatologists. METHODS: The Consortium of Rheumatology Researchers of North America (CORRONA) registry is an observational cohort with data on more than 33,000 RA patients. Using depression symptom measures reported separately by patients and rheumatologists, lifetime prevalence, 12-month prevalence, and annualised incidence rates (IR) were estimated...
July 2014: Clinical and Experimental Rheumatology
Danielle Diarra, Marina Stolina, Karin Polzer, Jochen Zwerina, Michael S Ominsky, Denise Dwyer, Adelheid Korb, Josef Smolen, Markus Hoffmann, Clemens Scheinecker, Desiree van der Heide, Robert Landewe, Dave Lacey, William G Richards, Georg Schett
Degenerative and inflammatory joint diseases lead to a destruction of the joint architecture. Whereas degenerative osteoarthritis results in the formation of new bone, rheumatoid arthritis leads to bone resorption. The molecular basis of these different patterns of joint disease is unknown. By inhibiting Dickkopf-1 (DKK-1), a regulatory molecule of the Wnt pathway, we were able to reverse the bone-destructive pattern of a mouse model of rheumatoid arthritis to the bone-forming pattern of osteoarthritis. In this way, no overall bone erosion resulted, although bony nodules, so-called osteophytes, did form...
February 2007: Nature Medicine
James R O'Dell, Ted R Mikuls, Thomas H Taylor, Vandana Ahluwalia, Mary Brophy, Stuart R Warren, Robert A Lew, Amy C Cannella, Gary Kunkel, Ciaran S Phibbs, Aslam H Anis, Sarah Leatherman, Edward Keystone
BACKGROUND: Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate--a common scenario in the management of rheumatoid arthritis. METHODS: We conducted a 48-week, double-blind, noninferiority trial in which we randomly assigned 353 participants with rheumatoid arthritis who had active disease despite methotrexate therapy to a triple regimen of disease-modifying antirheumatic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate...
July 25, 2013: New England Journal of Medicine
Uwe Pichlmeier, Kay-Uwe Heuer
OBJECTIVES: Methotrexate (MTX) is recognised as the cornerstone of treatment for rheumatoid arthritis. For some patients, oral MTX demonstrates variable bioavailability, especially at higher doses. Such concerns may be mitigated by subcutaneous (SC) MTX administration. This study investigated the relative bioavailability, safety, and tolerability of MTX administered either by SC injection with a prefilled autoinjector pen (MTX pen) or orally. METHODS: This single-centre, open-label, randomised, 2-period, 2-sequence, single-dose, crossover study enrolled healthy subjects aged 18 to 55 years into 1 of 4 dose groups (7...
July 2014: Clinical and Experimental Rheumatology
Josef S Smolen, Robert Landewé, Ferdinand C Breedveld, Maya Buch, Gerd Burmester, Maxime Dougados, Paul Emery, Cécile Gaujoux-Viala, Laure Gossec, Jackie Nam, Sofia Ramiro, Kevin Winthrop, Maarten de Wit, Daniel Aletaha, Neil Betteridge, Johannes W J Bijlsma, Maarten Boers, Frank Buttgereit, Bernard Combe, Maurizio Cutolo, Nemanja Damjanov, Johanna M W Hazes, Marios Kouloumas, Tore K Kvien, Xavier Mariette, Karel Pavelka, Piet L C M van Riel, Andrea Rubbert-Roth, Marieke Scholte-Voshaar, David L Scott, Tuulikki Sokka-Isler, John B Wong, Désirée van der Heijde
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches...
March 2014: Annals of the Rheumatic Diseases
Rebecca J Stack, Lilian H D van Tuyl, Maurits Sloots, Lotte A van de Stadt, Wijnanda Hoogland, Bertha Maat, Christian D Mallen, Rumandeep Tiwana, Karim Raza, Dirkjan van Schaardenburg
OBJECTIVE: The aim of this study was to explore symptoms and symptom development during the earliest phases of RA in patients with seropositive arthralgia and patients newly diagnosed with RA. METHODS: Interviews were conducted with 15 seropositive patients (anti-CCP positive, and often with arthralgia) and 11 newly presenting RA patients [classified according to the 2010 ACR/European League Against Rheumatism (EULAR) criteria]. Feedback procedures shared the experiences of seropositive arthralgia patients with early RA patients and vice versa...
September 2014: Rheumatology
Clive A Kelly, Vadivelu Saravanan, Mohamed Nisar, Subha Arthanari, Felix A Woodhead, Alec N Price-Forbes, Julie Dawson, Navtej Sathi, Yasmeen Ahmad, Gouri Koduri, Adam Young
OBJECTIVES: The prevalence of interstitial lung disease (ILD) in RA is ∼5%. Previous work identified increasing age, active articular disease and articular damage as risk factors for RA-associated ILD (RA-ILD). The roles of high-resolution CT (HRCT) and lung function testing in defining the nature and extent of pulmonary involvement have recently been explored. This study is the first to examine predictive and prognostic factors for the development of RA-ILD and to report on the physiological and radiological characteristics of the condition from a large multicentre UK network...
September 2014: Rheumatology
Yong-Jin Kwon, Sang-Won Lee, Yong-Beom Park, Soo-Kon Lee, Min-Chan Park
OBJECTIVE: This study was performed to investigate the effect of secreted frizzled-related protein 5 (Sfrp5), a novel anti-inflammatory adipokine that competes with the frizzled proteins for Wnt binding, on inflammatory response and the c-Jun N-terminal kinase (JNK) signalling pathway in RA. METHODS: Expression of Sfrp5 mRNA in peripheral blood mononuclear cells (PBMCs) and fibroblast-like synoviocytes (FLSs) from patients with RA and OA was determined using real-time quantitative PCR (qPCR)...
September 2014: Rheumatology
Barbara Hauser, Philip L Riches, James F Wilson, Annamarie E Horne, Stuart H Ralston
OBJECTIVE: Osteoporosis has previously been reported to be twice as common in patients with RA as in controls, but these studies predate the introduction of aggressive management of RA. The aim of this study was to evaluate the prevalence and clinical predictors of osteoporosis in RA in a contemporary cohort and to develop a clinical tool for the identification of patients at risk. METHODS: The prevalence of osteoporosis was related to clinical and demographic variables in 304 consecutive RA patients undergoing DXA at a single centre between 2009 and 2010 and compared with the frequency of osteoporosis in a population-based cohort of 903 subjects...
October 2014: Rheumatology
Serena Bugatti, Antonio Manzo, Barbara Vitolo, Francesca Benaglio, Elisa Binda, Martina Scarabelli, Frances Humby, Roberto Caporali, Costantino Pitzalis, Carlomaurizio Montecucco
OBJECTIVE: The B cell chemoattractant chemokine ligand 13 (CXCL13) is emerging as a new biochemical marker in RA. This study was undertaken to dissect the relationship between CXCL13 expression levels in the synovium and clinico-pathological variables relevant to RA pathogenesis and outcome. METHODS: Synovial tissues from 71 RA patients were evaluated by immunohistochemistry. Thirty paired samples were used for comparative gene expression analysis by quantitative real-time PCR...
October 2014: Rheumatology
Allan Wailoo, Mónica Hernández Alava, Ian C Scott, Fowzia Ibrahim, David L Scott
OBJECTIVE: The aim of this study was to estimate the cost-effectiveness of combination DMARDs with short-term glucocorticoids in early active RA using data from the 2-year Combination of Anti-Rheumatic Drugs in Early RA (CARDERA) trial. METHODS: CARDERA enrolled 467 patients with active RA of <24-months duration. All patients received MTX; half received step-down prednisolone and half ciclosporin in a placebo-controlled factorial design. Differences in mean costs and quality-adjusted life-years (QALYs) over 24-months follow-up were estimated using patient-level data from a UK health service perspective and 2011-12 costs...
October 2014: Rheumatology
M Cornillet, A Ruyssen-Witrand, A Constantin, O Meyer, A Cantagrel, G Serre, L Nogueira, L Nogueira, L Nogueira
BACKGROUND AND OBJECTIVE: In established RA, autoantibodies (AAB) to human citrullinated fibrinogen (AhFibA) were demonstrated to be mainly composed of two subfamilies of AAB directed to immunodominant epitopes borne by the fibrin peptides α36-50Cit38,42 and β60-74Cit60,72,74,respectively. Serum reactivity toward those peptides defines subgroups of patients. In the present study, we investigated whether AhFibA, anti-α36-50Cit38,42 and β60-74Cit60,72,74 AAB, have different predictive values for disease outcome in very early RA...
March 1, 2014: Annals of the Rheumatic Diseases
Jing Shi, Lotte A van de Stadt, Marije Verheul, E W Nivine Levarht, Tom W J Huizinga, Dörte Hamann, Dirkjan van Schaardenburg, René E M Toes, Leendert A Trouw
BACKGROUND AND OBJECTIVE: Anti-citrullinated protein antibodies (ACPA) and IgM-rheumatoid factor (IgM-RF) are auto-antibodies that can be detected many years before the clinical diagnosis of rheumatoid arthritis (RA). In recent studies we discovered a novel family of autoantibodies, anti-carbamylated protein (anti-CarP) antibodies. Carbamylation, like citrullination, is a post-translational modification of proteins. We observed that in RA, next to an antibody response against citrullinated proteins, also an immune response against carbamylated proteins exists...
March 1, 2014: Annals of the Rheumatic Diseases
2014-02-24 01:24:18
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"